Verona Pharma announces new collaborations to develop dry powder and MDI formulations for COPD
Verona Pharma has announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Leave a Reply
Want to join the discussion?Feel free to contribute!